Medical devices, healthcare technology and the business of care
PMA approval · P210036

PerClot Polysaccharide Hemostatic System

Baxter Healthcare Corporation · Decision date May 19, 2023

MEDTECHLEDGER EXPLANATIONP210036

What did the FDA approve?

FDA lists this as approval of the PerClot® Absorbable Hemostatic Powder, not a broader change to the whole PerClot® Polysaccharide Hemostatic System. The cited scope is surgical procedures, excluding neurological and ophthalmic use, as an adjunctive hemostatic device for suture line bleeding or capillary, venous and arteriolar bleeding.

The statement gives the intended use only; it does not provide a new indication, trial detail, or evidence summary in this record. It also does not say whether this was a first PMA or a supplement, so the relationship to an earlier PMA cannot be resolved from the supplied fields alone.

FDA approval order statement

Approval for the PerClot Absorbable Hemostatic Powder. The device is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of suture line bleeding or capillary, venous and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
May 19, 2023

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210036
Regulatory pathway
Premarket approval application
Product code
LMG
Decision code
APPR
Decision date
May 19, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Product code
LMG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210036 received

    Application receipt date recorded by FDA.

  2. P210036 · FDA decision

    APPR

  3. P210036/S010 · Related supplement

    PerClot Absorbable Hemostatic Powder Accessory Tips

Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210036

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA supplementNov 7, 2026FDA

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
ETHICON, Inc.PMA approvalOct 14, 1960FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Baxter Healthcare Corporation

Headquarters
Not reported
Brand website
baxter.com
FDA applicant address
25212 W. Illinois Rte. 120, Round Lake, IL, 60073

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records